A potential drug interaction between phenobarbital and dolutegravir: A case report.

[1]  S. Piscitelli,et al.  Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation , 2016, European Journal of Clinical Pharmacology.

[2]  I. Fong,et al.  A Case of a Potential Drug Interaction between Phenobarbital andDarunavir-based Antiretroviral Therapy , 2016 .

[3]  S. Piscitelli,et al.  Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir , 2014, European Journal of Clinical Pharmacology.

[4]  Yoshiaki Yamamoto,et al.  Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy , 2014, European Journal of Clinical Pharmacology.

[5]  A. Kashuba,et al.  Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir , 2013, Clinical Pharmacokinetics.

[6]  S. Piscitelli,et al.  Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans , 2013, Antimicrobial Agents and Chemotherapy.

[7]  Kelly A. Harmon,et al.  In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase Inhibitor , 2013, Drug Metabolism and Disposition.

[8]  K. Dooley,et al.  Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin: Results of a Phase 1 Study Among Healthy Subjects , 2013, Journal of acquired immune deficiency syndromes.

[9]  Yoshiaki Yamamoto,et al.  Influence of concomitant antiepileptic drugs on plasma lamotrigine concentration in adult Japanese epilepsy patients. , 2012, Biological & pharmaceutical bulletin.

[10]  S. Piscitelli,et al.  Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir , 2011, Antimicrobial Agents and Chemotherapy.

[11]  Shufeng Zhou,et al.  Clinical drugs that interact with St. John's wort and implication in drug development. , 2008, Current pharmaceutical design.

[12]  F. Gobbi,et al.  Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  M. Ratain,et al.  Effects of Green Tea Compounds on Irinotecan Metabolism , 2007, Drug Metabolism and Disposition.

[14]  A. J. van der Ven,et al.  Brief Report: Enzyme Inducers Reduce Elimination Half-Life After a Single Dose of Nevirapine in Healthy Women , 2006, Journal of acquired immune deficiency syndromes.

[15]  P. Kwan,et al.  Phenobarbital for the Treatment of Epilepsy in the 21st Century: A Critical Review , 2004, Epilepsia.

[16]  E. Perucca,et al.  Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs , 2003, The Lancet Neurology.

[17]  H K Kroemer,et al.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.

[18]  M. García-Sánchez,et al.  Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data , 1999, Biopharmaceutics & drug disposition.

[19]  E. Schuetz,et al.  Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. , 1996, Molecular pharmacology.